Video
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
Author(s):
Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Video Player is loading.
Rana McKay, MD, discusses the evolving treatment paradigm in the second-line setting for advanced renal cell carcinoma now that immunotherapy has revolutionized the first-line approach. McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center
Related Videos
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Related Content
